#SFHS2617244AFrance renews reimbursement listing for EXUFIBER absorbent wound dressings
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order renews and updates the reimbursement listing for EXUFIBER, a sterile high-absorption PVA fibre wound dressing made by Mölnlycke Health Care. It confirms that listed EXUFIBER formats remain covered for very exuding chronic wounds during the debridement phase. Healthcare providers, pharmacies, wound-care suppliers, and reimbursement teams should use the updated product codes, package sizes, and coverage references. The listed products remain covered until 1 June 2031.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Renews the reimbursement listing for EXUFIBER high-absorption PVA fibre wound dressings
- Updates the nomenclature with covered product codes, sizes, packaging, and reimbursement references
- Sets the end date for reimbursement coverage at 1 June 2031
Obligations
What this law requires
Use EXUFIBER only for reimbursed indication: very exuding chronic wounds during the debridement phase.
Before applying EXUFIBER, clean the wound with saline solution or water according to the applicable care protocol and carefully dry the surrounding skin.
Apply EXUFIBER to the wound without pre-moistening it, after selecting the appropriate dressing size, and secure it with an appropriate fixation system such as a secondary dressing or bandage.
Do not leave EXUFIBER in place for more than 7 days; replacement timing must depend on wound condition and clinical practice.
Change EXUFIBER when the dressing is completely saturated, at the first signs of leakage, or when required by clinical practice.